Evidence map›Paper›PMID 38326487›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Effectiveness of antipsychotics for managing agitated delirium in patients with advanced cancer: a secondary analysis of a multicenter prospective observational study in Japan (Phase-R).

Ken Kurisu, Shuji Inada, Isseki Maeda, Hiroyuki Nobata, Asao Ogawa, Satoru Iwase, Megumi Uchida, Tatsuo Akechi, Koji Amano, Nobuhisa Nakajima and 3 more

Open access · hybridAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Ken KurisuDepartment of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1831-8987
Shuji InadaDepartment of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Isseki MaedaDepartment of Palliative Care, Senri-Chuo Hospital, Osaka, Japan.
Hiroyuki NobataArata Clinic, Nagasaki, Japan.
Asao OgawaDepartment of Psycho-Oncology Service, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Satoru IwaseDepartment of Palliative Medicine, Saitama Medical University, Iruma, Saitama, Japan.
Megumi UchidaDepartment of Psychiatry and Cognitive-Behavioral Medicine, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Koji AmanoPalliative and Supportive Care Center, Osaka University Hospital, Osaka, Japan.
Nobuhisa NakajimaDivision of Community Medicine and International Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
Tatsuya MoritaDepartment of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan.
Masahiko SumitaniDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Kazuhiro YoshiuchiDepartment of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. kyoshiuc-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-8164-4910
Nagoya City University · JPThe University of Tokyo · JPHamamatsu University · JPNational Cancer Center Hospital East · JPOsaka University Hospital · JPSaitama Cancer Center · JPSaitama Medical University · JPUniversity of the Ryukyus · JPUniversity of Tokyo Hospital · JP

Funding

Japan Agency for Medical Research and Development 15ck0106059h0002
6 · The paper itself

Abstract

purposeDelirium is a common and serious comorbidity in patients with advanced cancer, necessitating effective management. Nonetheless, effective drugs for managing agitated delirium in patients with advanced cancer remain unclear in real-world settings. Thus, the present study aimed to explore an effective pharmacotherapy for this condition.

methodsWe conducted a secondary analysis of a multicenter prospective observational study in Japan. The analysis included patients with advanced cancer who presented with agitated delirium and received pharmacotherapy. Agitation was defined as a score of the Richmond Agitation-Sedation Scale for palliative care (RASS-PAL) of ≥ 1. The outcome was defined as -2 ≤ RASS-PAL ≤ 0 at 72 h after the initiation of pharmacotherapy. Multiple propensity scores were quantified using a multinomial logistic regression model, and adjusted odds ratios (ORs) were calculated for haloperidol, chlorpromazine, olanzapine, quetiapine, and risperidone.

resultsThe analysis included 271 patients with agitated delirium, and 87 (32%) showed -2 ≤ RASS-PAL ≤ 0 on day 3. The propensity score-adjusted OR of olanzapine was statistically significant (OR, 2.91; 95% confidence interval, 1.12 to 7.80; P = 0.030).

conclusionsThe findings suggest that olanzapine may effectively improve delirium agitation in patients with advanced cancer.

Indexed as

Antipsychotic AgentsDeliriumNeoplasmsHumansJapanOlanzapineAntipsychotic AgentsOlanzapineAdvanced cancerAgitationDeliriumOlanzapinePharmacotherapyRichmond agitation-sedation scale

Identifiers

PMID38326487
PMCPMC10850172
OpenAlexW4391648427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.